Trial Profile
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms DUART
- Sponsors AstraZeneca; AstraZeneca AB
- 05 Jan 2024 Status changed from active, no longer recruiting to completed.
- 28 Nov 2023 Planned End Date changed from 6 Jan 2024 to 13 Dec 2023.
- 24 Oct 2023 Results reporting primary safety and secondary efficacy analysis of DUART study presented at the 48th European Society for Medical Oncology Congress